Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions

American Heart Journal

Volumn 161, Issue 3, 2011, Pages 450-461

  White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; AZD 6482; CLOPIDOGREL; DZ 697B; E 5555; ELINOGREL; PLACEBO; PR 15; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; REVACEPT; TERUTROBAN; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BINDING; QT PROLONGATION; RISK FACTOR; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 79952370936     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.10.043     Document Type: Review

References (65)

1. Davi G., and Patrono C. Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
2. Jennings L.K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis Thromb Haemost 102 2009 248 257
3. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation Circ Res 100 2007 1261 1275 (Pubitemid 46742917)
4. Offermanns S. Activation of platelet function through G protein-coupled receptors Circ Res 99 2006 1293 1304 (Pubitemid 44949665)
5. Varga-Szabo D., Pleines I., and Nieswandt B. Cell adhesion mechanisms in platelets Arterioscler Thromb Vasc Biol 28 2008 403 412
6. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
7. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
8. Wiviott S.D., Braunwald E., and McCabe C.H. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
9. Yusuf S., Zhao F., and Mehta S.R. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
10. Wallentin L., Becker R.C., and Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
11. Manoukian S.V. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction Am J Cardiol 104 5 Suppl 2009 9C 15C
12. Eikelboom J.W., Mehta S.R., and Anand S.S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782 (Pubitemid 44268228)
13. Rao S.V., O'Grady K., and Pieper K.S. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206 (Pubitemid 41505393)
14. Mehran R., Pocock S.J., and Stone G.W. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur Heart J 30 2009 1457 1466
15. Anderson J.L., Adams C.D., and Antman E.M. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 e1 e157
16. Popma J.J., Ohman E.M., and Weitz J. Antithrombotic therapy in patients undergoing percutaneous coronary intervention Chest 119 1 Suppl 2001 321S 336S (Pubitemid 32154208)
17. Antithrombotic Trialists' Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
18. Bhatt D.L., Flather M.D., and Hacke W. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 2007 1982 1988 (Pubitemid 46694290)
19. Bhatt D.L., Fox K.A., and Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
20. Chen Z.M., Jiang L.X., and Chen Y.P. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
21. Mehta S.R., Bassand J.P., and Chrolavicius S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
22. Mehta S.R., Yusuf S., and Peters R.J. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
23. Sabatine M.S., Cannon C.P., and Gibson C.M. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189 (Pubitemid 40397259)
24. Steinhubl S.R., Berger P.B., and Mann J.T. III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420 (Pubitemid 35340537)
25. Mehta S.R., Tanguay J.F., and Eikelboom J.W. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
26. Becker R.C., Moliterno D.J., and Jennings L.K. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
27. Chackalamannil S., Wang Y., and Greenlee W.J. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J Med Chem 51 2008 3061 3064 (Pubitemid 351821864)
28. Effient (prasugrel) tablets [prescribing information] 2009 Eli Lilly and Company Indianapolis (Ind)
29. Gurbel P.A., Bliden K.P., and Antonino M.J. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients J Thromb Haemost 8 2010 43 53
30. Gurbel P.A., Bliden K.P., and Butler K. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
31. Jennings L.K., Earhart A., and Becker R.C. Thrombin receptor antagonist (TRA;SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics [abstract] Circulation 116 suppl)(16 2007 II 674 Abstract 3010
32. Leonardi S., Rao S.V., and Harrington R.A. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) Am Heart J 160 2010 65 72
33. Sabatine M.S. Novel antiplatelet strategies in acute coronary syndromes Cleve Clin J Med 76 suppl 1 2009 S8 S15
34. Schafer J.A., Kjesbo N.K., and Gleason P.P. Critical review of prasugrel for formulary decision makers J Manag Care Pharm 15 2009 335 343
35. Sugidachi A., Asai F., and Ogawa T. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties Br J Pharmacol 129 2000 1439 1446 (Pubitemid 30175717)
36. Teng R., Oliver S., and Hayes M.A. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects Drug Metab Dispos 38 2010 1514 1521
37. Raju N.C., Eikelboom J.W., and Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future Nat Clin Pract Cardiovasc Med 5 2008 766 780
38. Wiviott S.D., Braunwald E., and Angiolillo D.J. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
39. Montalescot G., Wiviott S.D., and Braunwald E. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
40. Wiviott S.D., Braunwald E., and McCabe C.H. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
41. Angiolillo D.J., Ueno M., and Goto S. Basic principles of platelet biology and clinical implications Circ J 74 2010 597 607
42. Chin C.T., Roe M.T., and Fox K.A. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 16 22.e1
43. Husted S., Emanuelsson H., and Heptinstall S. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
44. Berger J.S., Roe M.T., and Gibson C.M. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial Am Heart J 158 2009 998 1004.e1
45. Rao S. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor, vs. clopidogrel, as a novel antiplatelet therapy in patients undergoing non-urgent percutaneous coronary interventions (INNOVATE-PCI) Presented at the 2010 ESC Congress. August 28-September 1, 2010. Stockholm, Sweden 2010
46. Vandendries E.R., Hamilton J.R., and Coughlin S.R. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis Proc Natl Acad Sci USA 104 2007 288 292 (Pubitemid 46068024)
47. Derian C.K., Damiano B.P., and Addo M.F. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates J Pharmacol Exp Ther 304 2003 855 861 (Pubitemid 36152366)
48. Kato Y., Kita Y., and Hirasawa-Taniyama Y. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig Eur J Pharmacol 473 2003 163 169 (Pubitemid 36929880)
49. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology J Thromb Haemost 3 2005 1800 1814 (Pubitemid 41716567)
50. Hildemann S.K., and Bode C. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1 Hamostaseologie 29 2009 349 355
51. Chintala M., Vemulapalli S., and Kurowski S. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys Arterioscler Thromb Vasc Biol 28 2008 e138 e139 Abstract P579
52. Goto S., Yamaguchi T., and Ikeda Y. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome J Atheroscler Thromb 17 2010 156 164
53. Shinohara Y., Goto S., and Shimizu K. A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke [abstract] Int J Stroke suppl 1)(3 2008 139 Abstract PO01-193
54. Morrow D.A., Scirica B.M., and Fox K.A. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial Am Heart J 158 2009 335 341.e3
55. TRA*CER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale Am Heart J 158 2009 327 334.e4
56. Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects J Med Chem 49 18 2006 5389 5403 (Pubitemid 44373171)
57. Kogushi M., Yokohama H., and Kitamura S. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro J Thromb Haemost 5 Suppl 2 2007 Abstract P-M-059
58. Serebruany V.L., Kogushi M., and Dastros-Pitei D. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb Haemost 102 2009 111 119
59. Goto S., Ogawa H., and Takeuchi M. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 31 2010 2601 2613
60. O'Donoghue M. LANCELOT ACS: a prospective, randomized, double-blind, placebo-controlled trial of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndromes Presented at the 2010 TCT Congress. September 21-25, 2010. Washington, DC 2010
61. Combe S., Rosport K., and Kennedy A. PR-15 A novel intravenous inhibitor of platelet adhesion: a phase I dose ascending pharmacokinetic, pharmacodynamic, and tolerance study J Thromb Haemost 5 Suppl 2 2007 Abstract P-T-683
62. Zafar M.U., Ibanez B., and Choi B.G. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study Thromb Haemost 103 2010 205 212
63. Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention Cerebrovasc Dis 27 Suppl 3 2009 20 27
64. Celestini A., and Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients Vasc Health Risk Manag 3 2007 93 98 (Pubitemid 46860720)
65. Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H- pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it. Pub. No: WO/2009/093972. July 30, 2009.; World Intellectual Property Organization. (Available online at: http://www.wipo.int/pctdb/en/wo.jsp?WO=2009093972&IA=SE2009050065& DISPLAY=STATUS ). Last accessed September 29, 2010.